Satellite Symposia

md anderson logo

SATELLITE SYMPOSIUM SUPPORTED BY THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER

08.00 – 10.00 hours, Room: Mozart II

THE M.D. ANDERSON CANCER CENTER APROACH TO PATIENTS WITH HEMATOLOGIC MALIGNANCIES

Chair: M.J. Keating (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

08.00 – 08.25 hours

NEW TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA AND ACUTE LEUKEMIA

S. O’Brien (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

08.25 – 08.50 hours

OPTIMIZING TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

M.J. Keating (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

08.50 – 09.10 hours

USING CELULAR PHARMACOLOGY IN THE EVALUATION OF NEW AGENTS

V. Gandhi (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

09.10 – 09.35 hours

RECENT STUDIES IN ADULT AND PEDIATRIC ACUTE LEUKEMIA

H.M. Kantarjian (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

09.35 – 10.00 hours

IMM UNOMODULATORY THERAPY: EXPANDING TREATMENT OPTIONS IN MULTIPLE MYELOMA

D. Weber (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY SHIRE PHARMACEUTICALS

08.00 – 10.00 hours, Room: Mozart III

MYELOPROLIFERATI VE DISORDERS (MPDs) – ORIGINS AND EVOLUTION

08.00 – 08.30 hours breakfast

08.30 – 08.35 hours

INTRODUCTION AND WELCOME

Chair: H. Gisslinger (Medical University of Vienna, Vienna, Austria)

08.35 – 09.00 hours

THEPATHOGENESIS OF ET AND ITS RELATIONSHIP TO THE OTHER CHRONIC MPDs: HOW IS OUR KNOWLEDGE EVOLVING?

J. Spivak (Johns Hopkins Hospital, Baltimore, USA)

09.00 – 09.25 hours

MANAGEMENT OF ET: PROGRES IN THE CLINICAL PRACTICE OF PLATELET REDUCTION

G. Birgegård (University Hospital, Uppsala, Sweden)

09.25 – 09.50 hours

IN VESTIGATING NEW TARGETS IN MPDs: A MOLECULAR PERSPECTIVE

H. Pahl (University Hospital, Freiburg, Germany)

09.50 – 10.00 hours

PANEL DISCUSSION AND CLOSING REMARKS

H. Gisslinger (Medical University of Vienna, Vienna, Austria)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY MSD

>08.00 – 10.00 hours, Room: Lehár I + II

NEW THERAPEUTIC TARGETS IN HEMATOLOGIC MALIGNANCIES

Chair: J.-L. Harousseau (University Hospital Nantes, Nantes, France)

08.00 – 08.05 hours

WELCOME AND INTRODUCTION

J.-L. Harousseau (University Hospital Nantes, Nantes, France)

08.05 – 08.20 hours

TARGETING EPIGENETICS IN HEMATOLOGIC MALIGNANCIES/ HISTONE DEACETYLASE INHIBITORS (HDAC) OVERVIEW

M. Lübbert (University Freiburg Medical Center, Freiburg, Germany)

08.20 – 08.45 hours

HDAC IN LEUKEMIA AND MYELOMA

J.-L. Harousseau (University Hospital Nantes, Nantes, France)

08.45 – 09.15 hours

HDAC IN LYMPHOMA

M. Kirschbaum (City of Hope National Cancer Center, California, USA)

09.15 – 09.35 hours

EMERGING ROLES OF AURORA KINASE INHIBITORS IN CHRONIC MYELOGENOUS LEUKEMIA

F. Giles (University of Texas Health Science Centre, San Antonio, Texas, USA)

09.35 – 09.50 hours

MYELOPROLIFERATI VE DISORDERS: NEW APROACHES, NEW TARGETS

T. Barbui (Ospedali Riuniti di Bergamo, Bergamo, Italy)

09.50 – 10.00 hours

Q&A AND CLOSING REMARKS

J.-L. Harousseau (University Hospital Nantes, Nantes, France)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY MDS FOUNDATION

08.00 – 10.00 hours, Room: Lehár III + IV

MYELODYSPLASTIC SYNDROMES – INNOVATIONS , UNDERSTANDING AND ADVANCES

08.00 – 08.10 hours

INTRODUCTION

G.J. Mufti (King’s College Hospital, London, United Kingdom)

08.10 – 08.30 hours

GROWTH FACTORS : IMPACTING SURVIVAL IN MDS?

E. Hellström-Lindberg (Karolinska University Hospital and Institutet, Stockholm, Sweden)

08.30 – 08.50 hours

MDS PROGNOSIS – UNVEILING A REAL-TIME ASSESSMENT TOOL

L. Malcovati (University of Pavia, S. Matteo University Hospital, Pavia, Italy)

08.50 – 09.10 hours

THE ROLE OF REDUCED-INTENSITY REGIMENS IN HIGH-RISK MDS: DECISION GUIDELINES

Th. De Witte (Radboud University Medical Center, Nijmegen, The Netherlands)

09.10 – 09.30 hours

EPIGENETIC -BASIS FOR TREATMENT IN MDS

J-P. Issa (University of Texas M.D. Anderson Cancer Center, Houston, USA)

09.30 – 09.50 hours

CURRENT REVISIONS OF THE WHO CLASSIFICATION: CLINICAL IMPLICATIONS

J.M. Bennett (University of Rochester Medical Center, Rochester, USA)

09.50 – 10.00 hours

SUMMARY

P. Fenaux (Hôpital Avicenne, Bobigny, France)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY ALEXION

08:00 – 10:00 hours, Room: Stolz I

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA – PAT HOPHYSIOLOGY, MANAGEMENT AND QUALITY OF LIFE

Chair: H. Schrezenmeier (Institute for Transfusion Medicine, University of Ulm, Germany) Co-Chair: P. Hillmen (Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

08:00 – 08:25 hours

OVERVIEW ON DIAGNOSIS AND PATHOPHYSIOLOGY OF PNH

H. Schrezenmeier (Institute of Transfusion Medicine, University of Ulm, Germany)

08:25 – 08:55 hours

TREATMENT OF CORPUSCULAR HEMOLYSIS IN PNH

J. Schubert (Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany)

08:55 – 09:25 hours

PROP HYLAXIS AND TREATMENT OF THROMBOSIS IN PNH

P. Hillmen (Department of Haematology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

09:25 – 09:50 hours

IMPACT OF TREATMENT ON QUALITY OF LIFE

O. Chassany (Clinical Research Department, Assistance Publique - Hôpitaux de Paris, France)

09:50 – 10:00 hours

DISCUSSION

(Faculty)

[ Top of page ]

CME SATELLITE SYMPOSIUM SUPPORTED BY AN EDUCATIONAL GRANT FROM GlaxoSmithKline

08.00 – 10.00 hours, Room: Stolz II

OPTIMIZING STRATEGIES FOR TARGETING CD20 IN B-CEL LYMPHOPROLIFERATIVE DISORDERS

Chairs: B. Coiffier (Centre Hospitalier Lyon Sud, Pierre-Benite, France) J. Leonard (New York Weill Cornell Medical Center, New York, USA)

08:00 – 08:05 hours

WELCOME & INTRODUCTIONS

08:05 – 08:25 hours

INSIGHTS INTO MECHANISMS OF ACTION AND RESISTANCE OF ANTI- CD20 ANTIBODIES IN B-CEL LYMPHOPROLIFERATIVE DISORDERS

M. Glennie (Southampton General Hospital, Southampton, United Kingdom)

08:25 – 08:50 hours

TARGETING CD20 WITH CURRENT MONOCLONAL ANTIBODIES FOR PATIENTS WITH B-CEL LYMPHOMA:

J. Leonard (New York Weill Cornell Medical Center, New York, USA)

08:50 – 09:10 hours

EMERGING ROLE OF NEXT GENERATION ANTI CD20 ANTIBODIES IN B-CEL LYMPHOMAS:

O. O’Connor (Columbia University, New York, USA)

09:10 – 09:30 hours

EMERGING ROLE OF NEXT GENERATION ANTI CD20 ANTIBODIES IN CLL

B. Coiffier (Centre Hospitalier Lyon Sud, Pierre-Benite, France)

09:30 – 9:50 hours

TARGETING EFECTOR MOLECULES FOR B-CEL LYMPHOPROLIFERATI VE DISORDERS

R. Clynes (Columbia University, New York, USA)

09:50 – 10:00 hours

QUESTIONS AND PANEL DISCUSSION

10:00 hours

ADJOURN

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY PRIME ONCOLOGY

10.45 – 12.45 hours, Room: Mozart I

EMERGING THERAPIES IN HEMATOLOGICAL MALIGNANCIES

Chair: H.M. Kantarjian (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

10.45 – 10.50 hours

WELCOME AND INTRODUCTION

H.M. Kantarjian (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

10.50 – 11.10 hours

WHAT ’S NEW IN MANAGEMENT OF MYELODYSPLASTIC SYNDROMES?

P. Fenaux (Hôpital Avicenne, Bobigny, France)

11.10 – 11.25 hours

WHAT’S NEW IN MANAGEMENT OF IRON OVERLOAD IN MYELODYSPLASTIC SYNDROMES?

L. Malcovati (University of Pavia, S. Matteo University Hospital, Pavia, Italy)

11.25 – 11.40 hours

ELDERLY ACUTE MYELOGENOUS LEUKEMIA, A PROBLEM IN SEARCH OF A SOLUTION

H.M. Kantarjian (The University of Texas M.D. Anderson Cancer Center, Houston, USA)

11.40 – 12.00 hours

THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA IN THE ERA OF TYROSINE KINASE INHIBITORS

M. Baccarani (University of Bologna, Bologna, Italy)

12.00 – 12.20 hours

THE PLACE OF STEM CEL TRANSPLANT IN multiple myeloma IN THE ERA OF NOVEL THERAPIES

J.-L. Harousseau (University Hospital Hotel-Dieu, Nantes, France)

12.20 – 12.35 hours

IDIOPATHIC THROMBOCYTOPENIC PURPURA: EXCITING NEW THERAPY OPTIONS

A. Newland (The Royal London Hospital, London, United Kingdom)

12.35 – 12.45 hours

PANEL DISCUSSIONS AND FINAL REMARKS

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY F. HOFFMANN - LA ROCHE Ltd.

10.45 – 12.45 hours, Room: Strauss

WORKING TOGETHER – MAKING A DIFFERENCE TO CLL AND ANEMIC CANCER PATIENTS

10.45 – 10.55 hours

CHAIR’S WELCOME AND INTRODUCTION

U. Jäger (Medical University of Vienna, Vienna, Austria)

10.55 – 11.15 hours

THE ROLE OF RITUXIMAB IN THE FIRST-LINE TREATMENT OF CLL

E. Montserrat (Hospital Clinic Barcelona, Barcelona, Spain)

11.15 – 11.35 hours

THE ROLE OF RITUXIMAB IN THE TREATMENT OF RELAPSED CLL

V. Leblond (Pitié-Salpêtrière Hospital, Paris, France)

11.35 – 11.45 hours

AUDIENCE QUESTONS AND SUMMARY

U. Jäger (Medical University of Vienna, Vienna, Austria)

11.45 – 12.05 hours

EPOETIN BETA THERAPY – ACTING TO IMPROVE PATIENT CARE

G. Gaidano (Università del Piemonte Orientale Amedeo Avogadro, Novara, Italy)

12.05 – 12.25 hours

EPOETIN BETA AND I.V. IRON – WORKING TOGETHER TO OPTIMISE OUTCOMES

S. Agrawal (St. Bartholomew’s Hospital, London, United Kingdom)

12.25 – 12.35 hours

AUDIENCE QUESTIONS AND SUMMARY

U. Jäger (Medical University of Vienna, Vienna, Austria)

12.35 – 12.45 hours

FUTURE PERSPECTIVES AND CHAIR’S CLOSE

U. Jäger (Medical University of Vienna, Vienna, Austria)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY BAYER SCHERING PHARMA

10.45 – 12.45 hours, Room: Mozart II

REAL ADVANCES, REAL-LIFE CHALENGES: IMPROVING THE OUTLOOK FOR PATIENTS WITH NHL AND CLL

Chair: U. Vitolo (Azienda Ospedaliera S. Giovanni Battista, Turin, Italy)

10.45 – 10.50 hours

INTRODUCTION AND OVERVIEW

U. Vitolo (Azienda Ospedaliera S. Giovanni Battista, Turin, Italy)

10.50 – 11.15 hours

HOW TO IMPROVE THE STANDARD OF CARE IN NHL

A. Hagenbeek (University Medical Center, Utrecht, The Netherlands)

11.15 – 11.35 hours

TREATING NHL OUTSIDE CLINICAL TRIALS: REAL LIFE, REGISTRIES, AND GUIDELINES

L. Trümper (Georg-August-Universität, Göttingen, Germany)

11.35 – 11.55 hours

FLUDARABINE IN CLL: AN UPDATE ON RECENT FINDINGS

B. Cazin (Hôpital Claude Huriez, CHRU Lille, France)

11.55 – 12.20 hours

RIGHT FROM THE START : IMPROVING THE OUTLOOK IN CLL

P. Hillmen (Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom)

12.20 – 12.40 hours

PRACTICAL ISUES IN CLl MANAGEMENT

A. Österborg (Karolinska University Hospital, Stockholm, Sweden)

12.40 – 12.45 hours

CLOSING REMARKS

U. Vitolo (Azienda Ospedaliera S. Giovanni Battista, Turin, Italy)

12.45 hours

CLOSE

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY PHARMION

10.45 – 12.45 hours, Room Mozart III

CLINICAL BENEFITS AND SAFETY IN MULTIPLE MYELOMA TREATMENT : MAINTAINING THE BALANCE

Chair: H. Ludwig (Wilhelminenspital, Vienna, Austria)

10.45 – 10.50 hours

INTRODUCTION: MULTIPLE MYELOMA: TODAY’S MANAGEMENT CHALENGES

H. Ludwig (Wilhelminenspital, Vienna, Austria)

10.50 – 11.05 hours

NEWLY DIAGNOSED YOUNGER PATIENTS : CURRENT TREATMENT OPTIONS

J. San Miguel (Hospital Clinico University de Salamanca, Salamanca, Spain)

11.05 – 11.20 hours

ASSESSING THE CHOICES FOR THE NEWLY DIAGNOSED OLDER PATIENT

A. Palumbo (Ospedale San Giovanni Battista, Turin, Italy)

11.20 – 11.35 hours

MAINTENANCE THERAPY: WHAT ARE THE RECENT ADVANCES?

T. Facon (Centre Hospitalier Régional Universitaire de Lille, Lille, France)

11.35 – 11.50 hours

STRATEGIES FOR REFRACTORY DISEASE

M. Delforge (University Hospital, Leuven, Belgium)

11.50 – 12.40 hours

FACULTY AND AUDIENCE PARTICIPATION

Deep Venous Thrombosis, led by A. Palumbo
Peripheral Neuropathy, led by M. Delforge
Anemia, led by H. Ludwig
Other Potential Challenges, led by T. Facon

12.40 – 12.45 hours

SUMMARY AND CONCLUSIONS

H. Ludwig (Wilhelminenspital, Vienna, Austria)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY MUNDIPHARMA

10.45 – 12.45 hours, Room Lehár I+II

NEW & COMPELLING STRATEGIES TO COMBAT AND CHALLENGE CNS DISEASE.

Chairs: H. Dombret (Hôpital Saint-Louis, Paris, France)
W. Linkesch (University Clinic Graz, Graz, Austria)

10.45 – 10.55 hours

WELCOME AND INTRODUCTION

W. Linkesch (University Clinic Graz, Graz, Austria)

10.55 – 11.15 hours

HIGHLY SENSITIVE DIAGNOSTIC METHOD IN LEPTOMENINGEAL DISEASE

A. Orfao (Centro de Investigation del Cancer, Hospital Universitario y Universidad de Salamanca, Salamanca, Spain)

FROM TREATMENT TO PROPHYLAXIS OF CNS INVOLVEMENT:

11.15 – 11.35 hours

IN LYMPHOMA

A. Pinto (Centro di Riferimento Oncologico, Aviano, Italy)

11.35 – 11.55 hours

IN HIV POSITIVE PATIENS

M. Spina (National Cancer Institute Fondazione ‘G.Pascale’, Naples, Italy)

11.55 – 12.15 hours

ADVANCES IN CNS PROPHYLAXIS IN PCNSL

U. Schlegel / H. Pels (University of Bochum, Bochum, Germany)

12.15 – 12.35 hours

IN LEUKEMIA

N. Gökbuget (Klinikum der J.W.Goethe – Universität, Frankfurt, Germany)

12.35 – 12.45 hours

SUMMARY AND CONCLUSION

H. Dombret (Hôpital Saint-Louis, Paris, France)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY BIOENVISION

10.45 – 12.45 hours, Room: Lehár III + IV

ADVANCES IN ACUTE MYELOID LEUKEMIA: TREATMENT ACROS AGE GROUPS

Chair: S. Amadori (Tor Vergata University Hospital, Rome, Italy)

10.45 –10.50 hours

WELCOME AND INTRODUCTION

S. Amadori (Tor Vergata University Hospital, Rome, Italy)

10.50 – 11.15 hours

MANAGEMENT OF ELDERLY AML PATIENTS

A. Burnett (University of Wales, Cardiff, United Kingdom)

11.15 – 11.40 hours

AML IN YOUNGER ADULTS

A. Ganser (Hanover Medical School, Hanover, Germany)

11.40 – 12.05 hours

MANAGEMENT OF PEDIATRIC PATIENTS

P. Kearns (Birmingham Children’s Hospital, Birmingham, United Kingdom)

12.05 – 12.15 hours

DISCUSSION AND QUESTIONS

12.15 – 12.20 hours

CLOSING REMARKS

S. Amadori (Tor Vergata University Hospital, Rome, Italy)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY CEPHALON

10.45 – 12.45 hours, Room: Stolz I

TYROSINE KINASES AND THE FUTURE OF AML

Chair: B. Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands) M. Sanz (University Hospital La Fe, Valencia, Spain)

10.45 – 10.50 hours

INTRODUCTION

B. Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands)

10.50 – 11.20 hours

AML TODAY: REMAINING CHALENGES

B. Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands)

11.20 – 11.50 hours

NEW DEVELOPMENTS

F. Lo Coco (Tor Vergata University, Rome, Italy)

11.50 – 12.10 hours

OVERVIEW OF TYROSINE KINASES

M. Williams (Cephalon Inc., West Chester, P.A., USA)

12.10 – 12.30 hours

CLINICAL RESULTS TO DATE

A. Burnett (School of Medicine, Cardiff University, Cardiff, United Kingdom)

12.30 – 12.45 hours

PANEL DISCUSSION

M. Sanz (University Hospital La Fe, Valencia, Spain)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS ONCOLOGY

13.30 – 15.30 hours, Room: Mozart I

NEXT STEPS IN TARGETED THERAPY FOR CML

Chair: M. Baccarani (University of Bologna, Bologna, Italy)

13.30 – 13.40 hours

INTROUCTION AND BACKGROUND

M. Baccarani (University of Bologna, Bologna, Italy)

13.40 – 14:05 hours

NEW UNDERSTANDINGS OF IMATINIB RESPONSE

T. Hughes (Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia)

14.05 – 14.30 hours

PRACTICAL MANAGEMENT OF CML M.

O’Dwyer (University College Hospital, Galway, Ireland)

14.30 – 14.55 hours

WHICH MUTATIONS MATTER ?

S. Soverini (University of Bologna, Bologna, Italy)

14.55 – 15.25 hours

NILOTINIB : A NEW OPTION IN CML

F.J. Giles (University of Texas Health Science Center at San Antonio and Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, USA)

15.25 – 15.30 hours

SUMMARY AND CLOSE

M. Baccarani (University of Bologna, Bologna, Italy)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY F. HOFFMANN - LA ROCHE Ltd.

13.30 – 15.30 hours, Room: Strauss

MAINTAINING LIFE: OPTIMIZING TREATMENT STRATEGIES IN THE RITUXIMAB ERA

13.30 – 13.35 hours

CHAIR’S WELCOME AND INTRODUCTION

R. Marcus (Addenbrooke’s Hospital, Cambridge, UK)

13.35 – 13.55 hours

CHANGING THE NATURAL HISTORY OF FOLICULAR LYMPHOMA

R. Marcus (Addenbrooke’s Hospital, Cambridge, UK)

13.55 – 14.15 hours

RITUXIMAB MAINTENANCE THERAPY – A NEW STANDARD FOR RELAPSED FOLICULAR LYMPHOMA

A. Hagenbeek (University Medical Center, Utrecht, The Netherlands)

14.15 – 14.35 hours

R-CHOP IN AGRESIVE LYMPHOMA – SEVEN YEARS ON

A. Bosly (Mont-Godinne University Hospital, Yvoir, Belgium)

14.35 – 14.55 hours

OPTIMIZING THE USE OF RITUXIMAB IN RELAPSED AGRESIVE LYMPHOMA

M. Crump (Princess Margaret Hospital, Toronto, Canada)

14.55 – 15.15 hours

FUTURE PERSPECTIVES IN THE TREATMENT OF LYMPHOMAS USING A NEXT GENERATION CD20 ANTIBODY

P. Umaña (GLYCART, Schlieren, Switzerland)

15.15 – 15.25 hours

AUDIENCE QUESTIONS

15.25 – 15.30 hours

CHAIR’S CLOSE

R. Marcus (Addenbrooke’s Hospital, Cambridge, United Kingdom)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB ONCOLOGY

13.30 – 15.30 hours, Room: Mozart II

ADVANCES IN THE CLINICAL MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES

Chair: A. Hochhaus, (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

13.30 – 13.40 hours

WELCOME AND OUTLINE OF THE PROGRAME

A. Hochhaus (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

13.40 – 14.25 hours

SECTION 1: CML – NEW DIRECTIONS FOR DEVELOPMENT

Moderator: A. Hochhaus (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

13.40 – 14.00 hours

STEM CEL TRANSPLANTS

M. Copland (University of Glasgow, Glasgow, United Kingdom)

14.00 – 14.20 hours

MANAGING SUB-OPTIMAL RESPONSE IN CML

G. Rosti (Bologna University Hospital, Bologna, Italy)

14.20 – 14.25 hours

SUMMARY AND QUESTIONS

A. Hochhaus (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

14.25 – 15.00 hours

SECTION 2: PH+ AL – INCORPORATING THE NEW PARADIGM

Moderator: P. Rousselot (Hôpital Saint-Louis, Paris, France)

14.25 – 14.40 hours

THE GIMEMA EXPERIENCE

R. Foà (University La Sapienza, Rome, Italy)

14.40 – 14.55 hours

CLINICAL APROACHES IN THE EUROPEAN WORKING GROUP FOR ADULT ALL

O. Ottmann (Universitatsklinik Frankfurt, Frankfurt, Germany)

14.55 – 15.00 hours

SUMMARY AND QUESTIONS

Moderator: P. Rousselot (Hôpital Saint-Louis, Paris, France)

15.00 – 15.20 hours

SECTION 3: OTHER HEMATOLOGICAL MALIGNANCIES – WHERE ARE WE NOW?

Moderator: T. Facon (University Hospital, Lille, France)

15.00 – 15.15 hours

IDENTIFICATION OF MOLECULAR TARGETS AND TREATMENTS OPTIONS IN MYELOPROLIFERATI VE DISORDERS

A. Reiter (Klinikum Mannheim der Universitaet Heidelberg, Mannheim, Germany)

15.15 – 15.20 hours

SUMMARY AND QUESTIONS

Moderator: T. Facon (University Hospital, Lille, France)

15.20 – 15.30 hours

CONCLUSION AND QUESTIONS

A. Hochhaus (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY MUNDIPHARMA

13.30 - 15.30 hours, Room: Mozart III

NEW AND INNOVATIVE COMBINATIONS IN B- AND T-CELL MALIGNANCIES

Chairs: D. Hoelzer (Johann Wolfgang Goethe-University, Frankfurt, Germany) M. Keating (M.D. Anderson Cancer Center, Houston, USA)

13.30 – 14.00 hours

NEWS ON THE CLINICAL ACTIVITY OF BENDAMUSTINE IN CLL

AS SINGLE AGENT
W. Knauf (Bethanien Krankenhaus, Frankfurt, Germany)
IN COMBINATION
M. Hallek (Universität zu Köln, Cologne, Germany)

14.00 – 14.30 hours

COMBINATIONS USING NEW TARGETED AGENTS IN CLL

RECENT TRENDS IN DRUG COMBINATIONS IN CLL: AN OVERVIEW
M. Keating (M.D. Anderson Cancer Center, Houston, USA)
MODE OF ACTION AND FIRST CLINICAL RESULTS WITH FORODESINE
V. Gandhi (M.D. Anderson Cancer Center, Houston, USA)

14.30 – 14.45 hours

THE POTENTIAL OF BENDAMUSTINE IN NHL

J. Friedberg (University of Rochester, Rochester, USA)

14.45 – 15.00 hours

NEW PERSPECTIVES IN INDOLENT LYMPHOMAS: BENDAMUSTINE + RITUXIMAB

M. Rummel (University Hospital Giessen, Giessen, Germany)

15.00 – 15.15 hours

LIGHT IN THE TUNNEL OF TREATING AGRESIVE T-CEL MALIGNACIES

D. Hoelzer (Johann Wolfgang Goethe-University, Frankfurt, Germany)

15.15 – 15.30 hours

PANEL DISCUSSION

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY PHARMION

13.30 – 15.30 hours, Room Lehár I + II

THE CONTINUUM OF CARE IN MDS: MANAGEMENT STRATEGIES

13.30 – 13.35 hours

INTRODUCTION

P. Valent (Medical University of Vienna, Vienna, Austria)

13.35 – 14.00 hours

TARGETING DNA METHYLATION : THE RATIONALE FOR EPIGENETIC THERAPY

A.S. Yang (Norris Comprehensive Cancer Center, Los Angeles, USA)

14.00 – 14.25 hours

LOW -RISK PATIENTS : WHAT TREATMENT STRATEGIES MAKE SENSE?

M. Cazzola (University of Pavia Medical School, Pavia, Italy)

14.25 – 14.50 hours

TREATMENT STRATEGIES FOR ELDERLY HIGH-RISK MDS AND AML PATIENTS

H. Dombret (Hôpital Saint-Louis, Paris, France)

14.50 – 15.15 hours

LOOKING AHEAD: NOVEL APROACHES TO COMBINATION THERAPY IN MDS

J.-P. Issa (University of Texas M.D. Anderson Cancer Center, Houston, USA)

15.15 – 15.30 hours

DISCUSSION

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY CELGENE

13.30 – 15.30 hours, Rooms Lehár III + IV

LENALIDOMIDE: A NEW WAY FORWARD IN HEMATOLOGICAL MALIGNANCIES

Chair: H. Ludwig (Wilhelminenspital, Vienna, Austria)

13.30 – 13.35 hours

WELCOME AND INTRODUCTION

Chair: H. Ludwig (Wilhelminenspital, Vienna, Austria)

13.35 – 14.00 hours

PROLONGED SURVIVAL: A MILESTONE IN THE TREATMENT OF MULTIPLE MYELOMA

D. Weber (M.D. Anderson Cancer Center, Texas, USA)

14.00 – 14.25 hours

CLINICAL DECISION MAKING WITH LENALIDOMIDE: MULTIPLE MYELOMA CASES REVIEWED

Moderator: J. San Miguel (Hospital Universitario de Salamanca, Salamanca, Spain)

14.25 – 14.45 hours

CHANGING THE COURSE OF DISEASE IN MYELODYSPLASTIC SYNDROMES

P. Fenaux (Hôpital Avicenne, Paris, France)

14.45 – 15.10 hours

CLINICAL DECISION MAKING WITH LENALIDOMIDE: MYELODYSPLASTIC SYNDROMES CASES REVIEWED

Moderator: A. Giagounidis (St Johannes Hospital, Duisburg, Germany)

15.10 – 15.30 hours

LENALIDOMIDE BEYOND MULTIPLE MYELOMA AND MYELODYSPLASTIC SYNDROMES

M. Czuczman (Roswell Park Cancer Institute, New York, USA)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY ABBOTT MOLECULAR

13.30 – 15.30 hours, Room: Stolz I

THE ROLE OF MOLECULAR DIAGNOSTICS / FISH TECHNOLOGY IN HEMATOLOGICAL MALIGNANCIES

Chair: N. Heerema (Children’s Hospital of Columbus and Ohio State University, Columbus, USA)

GENETIC ANALYSIS OF ACUTE MYELOID LEUKEMIA

N. Van Roy (Center for Medical Genetics, University Hospital Ghent, Ghent, Belgium)

AN INTEGRATED APROACH TO THE DIAGNOSIS OF B-CEL LYMPHOPROLIFERATIVE DISORDERS

S. O’Connor (Haematological Malignancy Diagnostic Service (HMDS), Leeds General Infirmary, Leeds, United Kingdom)

CHROMOSOME ABNORMALITIES IN ACUTE LYMPHOBLASTIC LEUKEMIA: FISH STRATEGIES

N. Heerema (Children’s Hospital of Columbus and Ohio State University, Columbus, USA)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY NOVARTIS

16.15 – 18.15 hours, Room: Mozart I

TURNING THE SCIENCE OF IRON OVERLOAD INTO IRON CHELATION PRACTICE

16.15 – 16.20 hours

WELCOME & INTRODUCTION

Chair: J. Porter (University College London, London, United Kingdom)

16.20 – 16.45 hours

IRON OVERLOAD DIAGNOSIS, TREATMENT , AND MANAGEMENT GOALS

J. Porter (University College London, London, United Kingdom)

16.45 – 17.15 hours

APPLYING ADVANCES IN IRON CHELATION : REVIEW OF CURRENT TREATMENTS FOR CLINICAL PRACTICE

M. Cappellini (University of Milan, Milan, Italy)

17.15 – 17.40 hours

ADVANCES IN MANAGING TRANSFUSIONAL-RELATED IRON OVERLOAD: MDS CASE STUDY

A. Giagounidis (St. Johannes Hospital, Duisburg, Germany)

17.40 – 18.05 hours

NEW APROACHES FOR CHELATION THERAPY: BETA -THALASEMIA INTERMEDIA CASE STUDY

A. Taher (American University of Beirut Medical Center, Beirut, Lebanon)

18.05 – 18.15 hours

PANEL Q&A AND CLOSING REMARKS

Chair: J. Porter (University College London, London, United Kingdom)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY ORTHO BIOTECH, A DIVISION OF JANSSEN-CILAG

16.15 – 18.15 hours, Room: Strauss

NOVEL APROACHES IN THE MANAGEMENT OF HEMATOLOGICAL MALIGNANCIES

Co-Chairs: J.-P. Issa (M.D. Anderson Cancer Center, Houston, USA) H. Ludwig (Wilhelminenhospital, Vienna, Austria)

16.15 – 16.20 hours

WELCOME & INTRODUCTION

J.-P. Issa (M.D. Anderson Cancer Center, Houston, USA)

PART 1: NEW TREATMENT DIRECTIONS IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

16.20 – 16.35 hours

LOW -RISK MYELODYSPLASTIC SYNDROMES: WHEN SHOULD GROWTH FACTORS BE USED?

V. Santini (University of Florence, Florence, Italy)

16.35 – 16.50 hours

THERAPEUTIC POTENTIAL OF EPIGENETIC THERAPY IN THE BIOLOGICAL AND CLINICAL CONTINUUM OF MDS/AML

M. Lübbert (University of Freiburg Medical Center, Freiburg, Germany)

16.50 – 17.05 hours

ADVANCES IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES: UPDATE ON DECITABINE CLINICAL TRIALS

J.-P. Issa (M.D. Anderson Cancer Center, Houston, USA)

17.05 – 17.20 hours

UPDATE ON RECENT DEVELOPMENTS FOR THE TREATMENT OF ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA

J.-L. Harousseau (University Hospital Hotel-Dieu, Nantes, France)

PART 2: PROTEASOME INHIBITION WITH BORTE ZOMIB IN HEMATOLOGICAL MALIGNANCIES

17.20 – 17.35 hours

FRONT -LINE TREATMENT OF MULTIPLE MYELOMA: THE IMPACT OF BORTE ZOMIB

M. Kropff (Uniklinikum Munster, Munster, Germany)

17.35 – 17.50 hours

RISK -ADAPTED APROACHES IN MULTIPLE MYELOMA THERAPY

H. Ludwig (Wilhelminenhospital, Vienna, Austria)

17.50 – 18.05 hours

UTURE DIRECTIONS WITH BORTE ZOMIB IN HEMATOLOGICAL MALIGNANCIES

P.L. Zinzani (Seragnoli Institute, Bologna, Italy)

18.05 – 18.15 hours DISCUSSION AND CLOSING REMARKS H. Ludwig (Wilhelminenhospital, Vienna, Austria)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY BRISTOL-MYERS SQUIBB ONCOLOGY

16.15 – 18.15 hours, Room: Mozart II

OPTIMIZING RESPONSE IN CML – NEW APROACHES TO IMATINIB RESISTANCE IN CML

Chair: F. Guilhot (University Hospital (CHU), Poitiers, France)

16.15 – 16.20 hours

WELCOME AND INTRODUCTIONS

F. Guilhot (University Hospital (CHU), Poitiers, France)

16.20 – 16.50 hours

THE CAUSES, CONSEQUENCES AND DEFINITION OF IMATINIB RESISTANCE IN CML

M. Baccarani (University of Bologna, Bologna, Italy)

16.50 – 17.30 hours

OPTIMIZING THE MANAGEMENT OF THE IMATINIB RESISTANT CHRONIC PHASE CML PATIENT

16.50 – 17.10 hours

RESULTS FROM THE START C TRIAL

A. Hochhaus (Klinikum Mannheim der Universitat Heidelberg, Mannheim, Germany)

17.10 – 17.30 hours

RESULTS FROM THE START R TRIAL

H. Kantarjian (M.D. Anderson Cancer Center, Houston, USA)

17.30 – 18.00 hours

SHARING MANAGEMENT STRATEGIES IN THE CHRONIC CML PATIENT

F. Guilhot (University Hospital (CHU), Poitiers, France)

18.00 – 18.15 hours

PANEL Q&A AND CONCLUSIONS

F. Guilhot (University Hospital (CHU), Poitiers, France)

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY AMGEN

16.15 – 18.15 hours, Room: Mozart III

TAKING PATIENT CARE in hematology TO THE NEXT LEVEL

Chair: B. Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands)

16.15 – 16.20 hours

WELCOME

B. Löwenberg (Erasmus University Medical Center, Rotterdam, The Netherlands)

16.20 – 16.50 hours

UPDATE ON SURVIVAL DATA WITH ESAS IN CANCER PATIENTS

M. Hedenus (Sundsvall Hospital, Sundsvall, Sweden)

16.50 – 17.20 hours

CHALLENGING THE DOGMA OF “WATCH AND WAIT ” IN FOLICULAR LYMPHOMA

R. Pettengell (St. George’s Hospital Medical School, London, United Kingdom)

17.20 – 17.50 hours

AMG 531: A NOVEL THROMBOPOIESIS STIMULATING PEPTIBODY

D. Provan (GlaxoSmithKline, London, United Kingdom)

17.50 – 18.10 hours

TAKING PATIENT CARE IN HEMATOLOGY TO THE NEXT LEVEL

P. Fenaux (Hôpital Avicenne, Bobigny, France)

18.10 – 18.15 hours

CONCLUSIONS

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY GlaxoSmithKline

16.15 – 18.15 hours, Room Lehár I + II

MEETING THE TREATMENT CHALENGES OF CHRONIC IMUNE THROMBOCYTOPENIC PURPURA: AN INTERACTIVE CLINICAL DISCUSSION

16.15 – 16.30 hours

NEW DRUGS FOR FAMILIAR THERAPEUTIC TARGETS : THROMBOPOIETIN RECEPTOR AGONISTS AND ITP – INTERACTIVE INTRODUCTION

Program Chairman: D.J. Kuter (Massachusetts General Hospital, Boston, USA)

16.30 – 16.50 hours

ITP EPIDEMIOLOGY AND PAT HOPHYSIOLOGY

T. Gernsheimer (University of Washington School of Medicine, Seattle, USA)

16.50 – 17.00 hours

CLINICAL CASE INTERLUDE

D.J. Kuter (Massachusetts General Hospital, Boston, USA)

17.00 – 17.20 hours

FIRST-LINE ITP THERAPIES–BENEFITS AND LIMITATIONS

F. Rodeghiero (San Bortolo Hospital, Vicenza, Italy)

17.20 – 17.30 hours

CLINICAL CASE INTERLUDE

D.J. Kuter (Massachusetts General Hospital, Boston, USA)

17.30 – 17.50 hours

RATIONALE FOR AND REVIEW OF EMERGING STRATEGIES TO TREAT CHRONIC ITP

A. Newland (The Royal London Hospital, London, United Kingdom)

17.50 – 18.15 hours

NEW AGENTS AND EVOLVING MANAGEMENT PARADIGMS–CLINICAL CASE SUMMARY AND INTERACTIVE DISCUSSION

D.J. Kuter (Massachusetts General Hospital, Boston, USA) Faculty and Attendees

[ Top of page ]

SATELLITE SYMPOSIUM SUPPORTED BY GENZYME EUROPA

16.15 – 18.15 hours, Room: Lehár III + IV

THE RETURN OF THE SHERLOCK HOLMES APROACH TO DIAGNOSIS AND TREATMENT : BLEDING AS A CLUE IN RARE DISORDERS

16.15 – 16.25 hours

INTRODUCTION:

Chair: U. G. Jäger (Dept. of Medicine I, Div. of Hematology/ Hemostaseology, Medical University of Vienna, Austria)

16.25 – 16.40 hours

THE CASE OF THE HYPERACTIVE FEMALE

P. Huijgens (VU Hospital Medical Center, Amsterdam, The Netherlands)

16.40 – 16.55 hours

THE SURGEON’S SANGUINE SURPRISE

A. Mehta (Royal Free Hospital and University College Medical School, London, United Kingdom)

16.55 – 17.10 hours

THE CASE OF THE INSCRUTABLE SCROTUM

J. Van Droogenbroeck (Academic Hospital AZ St Jan AV, Brugge, Belgium)

17.10 – 17.25 hours

MYSTERY OF THE MISSING FACTOR ?

A. Mehta (Royal Free Hospital and University College Medical School, London, United Kingdom)

17.25 – 17.40 hours

A CASE OF HARMFUL PROTECTION

P. Huijgens (VU Hospital Medical Center, Amsterdam, The Netherlands)

17.40 – 17- 55 hours

PERFECT PARTNERS IN CRIME?

J. Van Droogenbroeck (Academic Hospital AZ St Jan AV, Brugge, Belgium)

17.55 – 18.15 hours

QUESTIONS, SUMMARY AND CONCLUSIONS

U.G. Jäger (Dept. of Medicine I, Div. of Hematology/Hemostaseology, Medical University of Vienna, Vienna, Austria)